正文部分

【访学雇用】美国克利夫兰诊所正在招收博士后、访问学者!

原标题:【访学雇用】美国克利夫兰诊所正在招收博士后、访问学者!

想要出国访问学习的幼友人望过来啦,美国克利夫兰诊所分子机制与转化肿瘤学倾向正在雇用博士后、访问学者职位!51访学网幼编每周五准时更新最新的访学雇用新闻,感谢关注51访学。

A fellowship position supported by the National Institutes of Health and the Prostate Cancer Foundation is available in the laboratory of Dr. Nima Sharifi at the Cleveland Clinic.

Our laboratory focuses on mechanistic discovery to understand the metabolic and molecular mechanisms of androgen synthesis and androgen receptor gain-of-function that lead to resistance to hormonal therapy. Specific areas include:

1) Metabolic and genetic changes required for hormone therapy resistance in prostate cancer and tumor progression

2) Clinical validation in patients and clinical trials using innovative approaches

3) Animal models of advanced prostate cancer for translational and therapeutic studies

4) Identifying targets for the development of new pharmacologic therapies

We discovered the first example of a gain-of-function in a steroid-synthesizing enzyme that enables prostate cancer resistance to hormonal therapy (Chang, et al. Cell. 2013;154:1074-84).

睁开全文

We also recently discovered that abiraterone works by conversion to a more active steroidal metabolite (Li, et al. Nature. 2015;523:347-51), that metabolism is pharmacologically modifiable to optimize therapy (Li, et al. Nature. 2016;533:547-51) and that these events are a class effect of steroidal androgen synthesis inhibitors (Alyamani, et al. Cell Chem Biol.2017;24:825-32) and genetic determination of metabolite generation (Alyamani, et al. J Clin Invest. 2018;128:3333-40).

This position is ideal for an individual with a strong interest in rapid translation of basic mechanistic discoveries to the bedside as this is a principal goal of the Sharifi Laboratory.

For example, we have shown that our discovery of a gain-of-function in a steroid-synthesizing enzyme is a predictive biomarker of poor outcomes after hormonal therapy (Hearn, et al. Lancet Oncol. 2016;17:1435-44; JAMAOncol. 2018;4:558-62).

We are currently evaluating this biomarker in an active clinical trial and are pursuing similar mechanisms and developing new treatment modalities based on these discoveries.

The position will provide a unique and multidisciplinary exposure to tumor metabolism, molecular oncology, drug development and clinical trials.

The ideal candidate has a Ph.D. or a visiting scholar in biochemistry, chemistry or molecular biology; has the appropriate expertise in discovery of molecular, biochemical or chemical mechanisms; and is highly driven. Outstanding verbal and communication skills are required. Interested candidates should send their CV and contact information for 3 references to:

Nima Sharifi, M.D.

Kendrick Family Chair for Prostate Cancer Research

Director, GU Malignancies Research Center

sharifn@ccf.org

院校简介

克利夫兰医学中央是世界最着名医疗机构之一,机构荟萃医疗、钻研和哺育三位一体,主销茅台酒挑供专科医疗和最新治疗方案的非营利性机构。克利夫兰医学中央起建于1921年2月28日 ,隶属于俄亥俄州一家非营利性公司——克利夫兰临床基金会,并由其经营。

克利夫兰医学中央本部位于克利夫兰市,在佛罗里达、内华达、添拿大和阿布扎比开设有分院。克利夫兰诊所本部共有超过1400个床位,整个医院系统拥有4400个床位。

在2017-2018年度全美最佳医院排名中,克利夫兰医学中央综相符排名位列全美第二,仅次于梅奥医学中央。其中央脏表科和泌尿表科为全美排名第一;普表科,风湿病以及肾脏内科位列第二;内排泄,骨科,呼吸科全美排名第三;妇产科和晚年病学排名第五;神经内/表科排名全美第六;肿瘤科排名第七;眼科学排名第九。 2018年12月,世界品牌实验室系统的《2018世界品牌500强》揭晓,克利夫兰诊所排名第200。

51访学网凝神国表访问学者申请服务,已累计数千名的成功医学访学案例,如安德森癌症中央、梅奥诊所、麻省总医院、布莱根妇女医院、斯坦福医院、JHU医院、克利夫兰诊所等顶尖医学中央访学案例星罗棋布。

所以,倘若你对访学有所有趣也许试一下。期待吾们能实现您医学访学的梦想!更众大夫访学有关题目,请增补51访学专科询问顾问于先生微信:woyaofangxue

51访学网精彩文章点击查望↓ ↓ ↓ ↓

Powered by 青海宏泰商贸咨询 @2018 RSS地图 html地图

Copyright 站群 © 2013-2018 版权所有